<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35179776</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-0215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>151</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of cancer</Title>
          <ISOAbbreviation>Int J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Repurposing autophagy regulators in brain tumors.</ArticleTitle>
        <Pagination>
          <StartPage>167</StartPage>
          <EndPage>180</EndPage>
          <MedlinePgn>167-180</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.33965</ELocationID>
        <Abstract>
          <AbstractText>Malignant brain tumors, such as glioblastoma multiforme (GBM) and brain metastases, continue to be an unmet medical challenge. Despite advances in cancer diagnostics and therapeutics, tumor cell colonization in the central nervous system renders most treatment options ineffective. This is primarily due to the selective permeability of the blood-brain barrier (BBB), which hinders the crossing of targeting agents into the brain. As such, repositioning medications that demonstrate anticancer effects and possess the ability to cross the BBB can be a promising option. Antidepressants, which are BBB-permeable, have been reported to exhibit cytotoxicity against tumor cells. Autophagy, specifically, has been identified as one of the common key mediators of antidepressant's antitumor effects. In this work, we provide a comprehensive overview of US Food and Drug Administration (FDA)-approved antidepressants with reported cytotoxic activities in different tumor models, where autophagy dysregulation was demonstrated to play the main part. As such, imipramine, maprotiline, fluoxetine and escitalopram were shown to induce autophagy, whereas nortriptyline, clomipramine and paroxetine were identified as autophagy inhibitors. Sertraline and desipramine, depending on the neoplastic context, were demonstrated to either induce or inhibit autophagy. Collectively, these medications were associated with favorable therapeutic outcomes in a variety of cancer cell models, including brain tumors.</AbstractText>
          <CopyrightInformation>© 2022 UICC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Petrosyan</LastName>
            <ForeName>Edgar</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-2543-3617</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fares</LastName>
            <ForeName>Jawad</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-5368-8764</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cordero</LastName>
            <ForeName>Alex</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rashidi</LastName>
            <ForeName>Aida</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arrieta</LastName>
            <ForeName>Víctor A</ForeName>
            <Initials>VA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanojia</LastName>
            <ForeName>Deepak</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lesniak</LastName>
            <ForeName>Maciej S</ForeName>
            <Initials>MS</Initials>
            <Identifier Source="ORCID">0000-0002-0096-5107</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Northwestern Medicine Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50CA221747</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01NS87990</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35CA197725</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01NS093903</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS115955</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50CA221747</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01NS093903</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01NS87990</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35CA197725</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Int J Cancer</MedlineTA>
        <NlmUniqueID>0042124</NlmUniqueID>
        <ISSNLinking>0020-7136</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antidepressants</Keyword>
        <Keyword MajorTopicYN="N">blood brain barrier</Keyword>
        <Keyword MajorTopicYN="N">brain metastasis</Keyword>
        <Keyword MajorTopicYN="N">cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">repositioning</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35179776</ArticleId>
        <ArticleId IdType="doi">10.1002/ijc.33965</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>American Cancer Society. Key Statistics for Brain and Spinal Cord Tumors, USA: American Cancer Society; 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41-58.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Zhou L, Xie N, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5:113.</Citation>
        </Reference>
        <Reference>
          <Citation>Fares J, Kanojia D, Rashidi A, Ulasov I, Lesniak MS. Genes that mediate metastasis across the blood-brain barrier. Trends Cancer. 2020;6:660-676.</Citation>
        </Reference>
        <Reference>
          <Citation>Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26:690-702.</Citation>
        </Reference>
        <Reference>
          <Citation>Morselli E, Galluzzi L, Kepp O, et al. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta. 2009;1793:1524-1532.</Citation>
        </Reference>
        <Reference>
          <Citation>Gammoh N, Fraser J, Puente C, et al. Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy. 2016;12:1431-1439.</Citation>
        </Reference>
        <Reference>
          <Citation>Catalano M, D'Alessandro G, Lepore F, et al. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol. 2015;9:1612-1625.</Citation>
        </Reference>
        <Reference>
          <Citation>Aoki H, Kondo Y, Aldape K, et al. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy. 2008;4:467-475.</Citation>
        </Reference>
        <Reference>
          <Citation>Tini P, Belmonte G, Toscano M, et al. Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma. Biomed Res Int. 2015;2015:208076.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdul Rahim SA, Dirkse A, Oudin A, et al. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. Br J Cancer. 2017;117:813-825.</Citation>
        </Reference>
        <Reference>
          <Citation>Azad MB, Chen Y, Henson ES, et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy. 2008;4:195-204.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou Y, Wang Q, Li B, Xie B, Wang W. Temozolomide induces autophagy via ATMAMPKULK1 pathways in glioma. Mol Med Rep. 2014;10:411-416.</Citation>
        </Reference>
        <Reference>
          <Citation>Goncalves RM, Agnes JP, Delgobo M, et al. Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas. Biochem Pharmacol. 2019;163:440-450.</Citation>
        </Reference>
        <Reference>
          <Citation>Jing K, Lim K. Why is autophagy important in human diseases? Exp Mol Med. 2012;44:69-72.</Citation>
        </Reference>
        <Reference>
          <Citation>Murrow L, Debnath J. Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease. Annu Rev Pathol. 2013;8:105-137.</Citation>
        </Reference>
        <Reference>
          <Citation>Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal. 2014;20:460-473.</Citation>
        </Reference>
        <Reference>
          <Citation>Zachari M, Ganley IG. The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 2017;61:585-596.</Citation>
        </Reference>
        <Reference>
          <Citation>Hollenstein DM, Kraft C. Autophagosomes are formed at a distinct cellular structure. Curr Opin Cell Biol. 2020;65:50-57.</Citation>
        </Reference>
        <Reference>
          <Citation>Abada A, Elazar Z. Getting ready for building: signaling and autophagosome biogenesis. EMBO Rep. 2014;15:839-852.</Citation>
        </Reference>
        <Reference>
          <Citation>Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349-364.</Citation>
        </Reference>
        <Reference>
          <Citation>Reggiori F, Ungermann C. Autophagosome maturation and fusion. J Mol Biol. 2017;429:486-496.</Citation>
        </Reference>
        <Reference>
          <Citation>Nascimbeni AC, Codogno P, Morel E. Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. FEBS J. 2017;284:1267-1278.</Citation>
        </Reference>
        <Reference>
          <Citation>Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2011;7:279-296.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132-141.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou H, Huang S. The complexes of mammalian target of rapamycin. Curr Protein Pept Sci. 2010;11:409-424.</Citation>
        </Reference>
        <Reference>
          <Citation>Ballesteros-Alvarez J, Andersen JK. mTORC2: the other mTOR in autophagy regulation. Aging Cell. 2021;20:e13431.</Citation>
        </Reference>
        <Reference>
          <Citation>Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol. 2012;32:2-11.</Citation>
        </Reference>
        <Reference>
          <Citation>Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26:2694-2701.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Whiteman MW, Lian H, et al. A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem. 2009;284:21412-21424.</Citation>
        </Reference>
        <Reference>
          <Citation>Errafiy R, Aguado C, Ghislat G, et al. PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity. PLoS One. 2013;8:e83318.</Citation>
        </Reference>
        <Reference>
          <Citation>Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214-226.</Citation>
        </Reference>
        <Reference>
          <Citation>Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009;28:677-685.</Citation>
        </Reference>
        <Reference>
          <Citation>Woods A, Dickerson K, Heath R, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005;2:21-33.</Citation>
        </Reference>
        <Reference>
          <Citation>Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11:709-730.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu R, Ji Z, Xu C, Zhu J. The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e12912.</Citation>
        </Reference>
        <Reference>
          <Citation>Rosenfeld MR, Ye X, Supko JG, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014;10:1359-1368.</Citation>
        </Reference>
        <Reference>
          <Citation>Compter I, Eekers D, Hoeben A, et al. CHLOROBRAIN phase IB trial: the addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma. Ann Oncol. 2019;30:V154.</Citation>
        </Reference>
        <Reference>
          <Citation>Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A, et al. Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol. 2013;8:209.</Citation>
        </Reference>
        <Reference>
          <Citation>Moraczewski J, Aedma KK. Tricyclic Antidepressants. Treasure Island: StatPearlsed Publishing; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Bielecka AM, Obuchowicz E. Antidepressant drugs as a complementary therapeutic strategy in cancer. Exp Biol Med (Maywood). 2013;238:849-858.</Citation>
        </Reference>
        <Reference>
          <Citation>Arimochi H, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol. 2006;541:17-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Serafeim A, Holder MJ, Grafton G, et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood. 2003;101:3212-3219.</Citation>
        </Reference>
        <Reference>
          <Citation>Fayez R, Gupta V. Imipramine. Treasure Island: StatPearlsed Publishing; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Jeon SH, Kim SH, Kim Y, et al. The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 2011;413:311-317.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma J, Hou LN, Rong ZX, et al. Antidepressant desipramine leads to C6 glioma cell autophagy: implication for the adjuvant therapy of cancer. Anticancer Agents Med Chem. 2013;13:254-260.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25-32.</Citation>
        </Reference>
        <Reference>
          <Citation>Shchors K, Massaras A, Hanahan D. Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell. 2015;28:456-471.</Citation>
        </Reference>
        <Reference>
          <Citation>Czajkowski R, Lei L, Sabala P, Baranska J. ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12). FEBS Lett. 2002;513:179-183.</Citation>
        </Reference>
        <Reference>
          <Citation>Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death: apoptosis, autophagy and senescence. FEBS J. 2010;277:2-21.</Citation>
        </Reference>
        <Reference>
          <Citation>Kuzu OF, Gowda R, Noory MA, Robertson GP. Modulating cancer cell survival by targeting intracellular cholesterol transport. Br J Cancer. 2017;117:513-524.</Citation>
        </Reference>
        <Reference>
          <Citation>Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014;13:1690-1703.</Citation>
        </Reference>
        <Reference>
          <Citation>Chung PED, Gendoo DMA, Ghanbari-Azarnier R, et al. Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. Nat Commun. 2020;11:1825.</Citation>
        </Reference>
        <Reference>
          <Citation>Donohue E, Thomas A, Maurer N, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer. 2013;4:585-596.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen M, He M, Song Y, et al. The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. Int J Mol Med. 2014;34:276-282.</Citation>
        </Reference>
        <Reference>
          <Citation>Fitzwalter BE, Towers CG, Sullivan KD, et al. Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover. Dev Cell. 2018;44:555-565.</Citation>
        </Reference>
        <Reference>
          <Citation>Sigmond J, Honeywell RJ, Postma TJ, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol. 2009;20:182-187.</Citation>
        </Reference>
        <Reference>
          <Citation>Rossi M, Munarriz ER, Bartesaghi S, et al. Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux. J Cell Sci. 2009;122:3330-3339.</Citation>
        </Reference>
        <Reference>
          <Citation>Rossi M, Rotblat B, Ansell K, et al. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis. 2014;5:e1203.</Citation>
        </Reference>
        <Reference>
          <Citation>Nguyen HG, Yang JC, Kung HJ, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014;33:4521-4530.</Citation>
        </Reference>
        <Reference>
          <Citation>Bongiorno-Borbone L, Giacobbe A, Compagnone M, et al. Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. Oncotarget. 2015;6:16926-16938.</Citation>
        </Reference>
        <Reference>
          <Citation>Cloonan SM, Williams DC. The antidepressants maprotiline and fluoxetine induce type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer. 2011;128:1712-1723.</Citation>
        </Reference>
        <Reference>
          <Citation>Hsu SS, Chen WC, Lo YK, et al. Effect of the antidepressant maprotiline on Ca2+ movement and proliferation in human prostate cancer cells. Clin Exp Pharmacol Physiol. 2004;31:444-449.</Citation>
        </Reference>
        <Reference>
          <Citation>Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. Treasure Island: StatPearlsed Publishing; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life Sci. 1974;15:1161-1171.</Citation>
        </Reference>
        <Reference>
          <Citation>Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry. 2004;3:2.</Citation>
        </Reference>
        <Reference>
          <Citation>Sun D, Zhu L, Zhao Y, et al. Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. Cell Prolif. 2018;51:e12402.</Citation>
        </Reference>
        <Reference>
          <Citation>Tamargo-Gomez I, Marino G. AMPK: regulation of metabolic dynamics in the context of autophagy. Int J Mol Sci. 2018;19:3812.</Citation>
        </Reference>
        <Reference>
          <Citation>Bowie M, Pilie P, Wulfkuhle J, et al. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol. 2015;6:299-311.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018;22:1167-1178.</Citation>
        </Reference>
        <Reference>
          <Citation>Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell Res. 2014;24:24-41.</Citation>
        </Reference>
        <Reference>
          <Citation>Ichimura Y, Komatsu M. Selective degradation of p62 by autophagy. Semin Immunopathol. 2010;32:431-436.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang K, Gong Q, Zhan Y, et al. Blockage of autophagic flux and induction of mitochondria fragmentation by paroxetine hydrochloride in lung cancer cells promotes apoptosis via the ROS-MAPK pathway. Front Cell Dev Biol. 2019;7:397.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang K, Chen B, Yin T, et al. N-methylparoxetine blocked autophagic flux and induced apoptosis by activating ROS-MAPK pathway in non-small cell lung cancer cells. Int J Mol Sci. 2019;20:3415.</Citation>
        </Reference>
        <Reference>
          <Citation>Yue J, Lopez JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 2020;21:2346.</Citation>
        </Reference>
        <Reference>
          <Citation>Chinnapaka S, Bakthavachalam V, Munirathinam G. Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: dual activation of apoptosis and autophagy signaling by deregulating redox balance. Am J Cancer Res. 2020;10:2043-2065.</Citation>
        </Reference>
        <Reference>
          <Citation>Xia D, Zhang YT, Xu GP, Yan WW, Pan XR, Tong JH. Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells. Leuk Lymphoma. 2017;58:1-10.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang X, Lu W, Shen X, et al. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI. Insight. 2018;3:e98921.</Citation>
        </Reference>
        <Reference>
          <Citation>Zinnah KMA, Seol JW, Park SY. Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation. Int J Mol Med. 2020;46:795-805.</Citation>
        </Reference>
        <Reference>
          <Citation>van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1-12.</Citation>
        </Reference>
        <Reference>
          <Citation>Fernandes C, Costa A, Osorio L, et al. Current standards of care in glioblastoma therapy. In: de Vleeschouwer S, ed. Glioblastomaed. Brisbane: Codon Publications; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Sun H, Yakisich JS. Overcoming the blood-brain barrier for chemotherapy: limitations, challenges and rising problems. Anticancer Agents Med Chem. 2014;14:1085-1093.</Citation>
        </Reference>
        <Reference>
          <Citation>Pottegard A, Garcia Rodriguez LA, Rasmussen L, Damkier P, Friis S, Gaist D. Use of tricyclic antidepressants and risk of glioma: a nationwide case-control study. Br J Cancer. 2016;114:1265-1268.</Citation>
        </Reference>
        <Reference>
          <Citation>Walker AJ, Card T, Bates TE, Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer. 2011;104:193-197.</Citation>
        </Reference>
        <Reference>
          <Citation>Otto-Meyer S, DeFaccio R, Dussold C, et al. A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. Brain Behav Immun Health. 2020;2:100025.</Citation>
        </Reference>
        <Reference>
          <Citation>Berge LAM, Andreassen BK, Stenehjem JS, et al. Use of antidepressants and risk of cutaneous melanoma: a prospective registry-based case-control study. Clin Epidemiol. 2020;12:193-202.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu W, Tamim H, Shapiro S, Stang MR, Collet JP. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol. 2006;7:301-308.</Citation>
        </Reference>
        <Reference>
          <Citation>Toh S, Rodriguez LA, Hernandez-Diaz S. Use of antidepressants and risk of lung cancer. Cancer Causes Control. 2007;18:1055-1064.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang J, Zeng C, Xiao J, et al. Association between depression and brain tumor: a systematic review and meta-analysis. Oncotarget. 2017;8:94932-94943.</Citation>
        </Reference>
        <Reference>
          <Citation>Escamilla-Ramirez A, Castillo-Rodriguez RA, Zavala-Vega S, et al. Autophagy as a potential therapy for malignant glioma. Pharmaceuticals (Basel). 2020;13:156.</Citation>
        </Reference>
        <Reference>
          <Citation>Simpson JE, Gammoh N. The impact of autophagy during the development and survival of glioblastoma. Open Biol. 2020;10:200184.</Citation>
        </Reference>
        <Reference>
          <Citation>Colella B, Faienza F, Carinci M, et al. Autophagy induction impairs Wnt/beta-catenin signalling through beta-catenin relocalisation in glioblastoma cells. Cell Signal. 2019;53:357-364.</Citation>
        </Reference>
        <Reference>
          <Citation>Koukourakis MI, Mitrakas AG, Giatromanolaki A. Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. Br J Cancer. 2016;114:485-496.</Citation>
        </Reference>
        <Reference>
          <Citation>Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23.</Citation>
        </Reference>
        <Reference>
          <Citation>Jo GH, Bogler O, Chwae YJ, et al. Radiation-induced autophagy contributes to cell death and induces apoptosis partly in malignant glioma cells. Cancer Res Treat. 2015;47:221-241.</Citation>
        </Reference>
        <Reference>
          <Citation>Khan I, Baig MH, Mahfooz S, et al. Deciphering the role of autophagy in treatment of resistance mechanisms in glioblastoma. Int J Mol Sci. 2021;22:1318.</Citation>
        </Reference>
        <Reference>
          <Citation>Taylor MA, Das BC, Ray SK. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 2018;23:563-575.</Citation>
        </Reference>
        <Reference>
          <Citation>Li L, Liu WL, Su L, Lu ZC, He XS. The role of autophagy in cancer radiotherapy. Curr Mol Pharmacol. 2020;13:31-40.</Citation>
        </Reference>
        <Reference>
          <Citation>Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27-42.</Citation>
        </Reference>
        <Reference>
          <Citation>Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28.</Citation>
        </Reference>
        <Reference>
          <Citation>Cordero A, Kanojia D, Miska J, et al. FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis. Oncogene. 2019;38:6445-6460.</Citation>
        </Reference>
        <Reference>
          <Citation>Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol. 2010;22:241-245.</Citation>
        </Reference>
        <Reference>
          <Citation>Maiti A, Hait NC. Autophagy-mediated tumor cell survival and progression of breast cancer metastasis to the brain. J Cancer. 2021;12:954-964.</Citation>
        </Reference>
        <Reference>
          <Citation>Santana-Codina N, Muixi L, Foj R, et al. GRP94 promotes brain metastasis by engaging pro-survival autophagy. Neuro Oncol. 2020;22:652-664.</Citation>
        </Reference>
        <Reference>
          <Citation>Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol. 2000;151:951-957.</Citation>
        </Reference>
        <Reference>
          <Citation>Moorman PG, Grubber JM, Millikan RC, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology. 2003;14:307-314.</Citation>
        </Reference>
        <Reference>
          <Citation>Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat. 2008;112:123-132.</Citation>
        </Reference>
        <Reference>
          <Citation>Gatto F, Milletti G, Carai A, Mastronuzzi A, Nazio F. Recent advances in understanding the role of autophagy in paediatric brain tumours. Diagnostics (Basel). 2021;11:481.</Citation>
        </Reference>
        <Reference>
          <Citation>Paul R, Bharambe H, Shirsat NV. Autophagy inhibition impairs the invasion potential of medulloblastoma cells. Mol Biol Rep. 2020;47:5673-5680.</Citation>
        </Reference>
        <Reference>
          <Citation>Singh SV, Dakhole AN, Deogharkar A, et al. Restoration of miR-30a expression inhibits growth, tumorigenicity of medulloblastoma cells accompanied by autophagy inhibition. Biochem Biophys Res Commun. 2017;491:946-952.</Citation>
        </Reference>
        <Reference>
          <Citation>Cancer M, Hutter S, Holmberg KO, et al. Humanized stem cell models of pediatric Medulloblastoma reveal an Oct4/mTOR Axis that promotes malignancy. Cell Stem Cell. 2019;25:855-870.</Citation>
        </Reference>
        <Reference>
          <Citation>Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 1998;273:3963-3966.</Citation>
        </Reference>
        <Reference>
          <Citation>Zahedi S, Fitzwalter BE, Morin A, et al. Effect of early-stage autophagy inhibition in BRAF(V600E) autophagy-dependent brain tumor cells. Cell Death Dis. 2019;10:679.</Citation>
        </Reference>
        <Reference>
          <Citation>Miele E, Buttarelli FR, Arcella A, et al. High-throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol. 2014;16:228-240.</Citation>
        </Reference>
        <Reference>
          <Citation>He X, Zhang L, Chen Y, et al. The G protein alpha subunit Galphas is a tumor suppressor in sonic hedgehog-driven medulloblastoma. Nat Med. 2014;20:1035-1042.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldhoff P, Warrington NM, Limbrick DD Jr, et al. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res. 2008;14:7717-7725.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007;67:651-658.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmidt AL, de Farias CB, Abujamra AL, et al. BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells. J Mol Neurosci. 2010;40:303-310.</Citation>
        </Reference>
        <Reference>
          <Citation>Evans A, Wein A, Hemenway M, Kissell E, Polito A, Madden J. NU-20 antidepressant usage in pediatric brain tumor patients. Neuro Oncol. 2016;18:138.</Citation>
        </Reference>
        <Reference>
          <Citation>Bahmad HF, Elajami MK, El Zarif T, Bou-Gharios J, Abou-Antoun T, Abou-Kheir W. Drug repurposing towards targeting cancer stem cells in pediatric brain tumors. Cancer Metastasis Rev. 2020;39:127-148.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
